Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2012 pubmed 37 citations

Interaction structure of the complex between neuroprotective factor humanin and Alzheimer's β-amyloid peptide revealed by affinity mass spectrometry and molecular modeling.

Maftei. Madalina M; Tian. Xiaodan X; Manea. Marilena M; Exner. Thomas E TE; Schwanzar. Daniel D; von Arnim. Christine A F CA; Przybylski. Michael M

Key Findings

  • Humanin binds specifically to beta‑amyloid (Aβ1‑40) via its 5‑15 region, while Aβ’s 17‑28 segment is the contact point.
  • The binding affinity (K_D) of the humanin‑Aβ complex is ~610 nM, indicating a moderate‑strength interaction.
  • Molecular modeling and dynamics simulations support the identified binding sites and suggest how humanin may shield toxic Aβ regions.

Practical Outcomes

  • For biohackers, this study shows humanin has a real, measurable interaction with Alzheimer‑linked peptides, supporting its potential as a neuroprotective agent. However, no dosage, safety, or efficacy data in humans are provided, so it’s not yet ready for direct supplementation or protocol changes.

Summary

Scientists mapped how the tiny 24‑amino‑acid peptide humanin sticks to the Alzheimer‑related beta‑amyloid protein, pinpointing the exact parts of each that lock together and measuring a moderate binding strength (about 610 nM). This helps explain why humanin can protect brain cells in lab tests, but it’s still early‑stage research, not a ready‑to‑use supplement guide.

Abstract

Humanin (HN) is a linear 24-aa peptide recently detected in human Alzheimer's disease (AD) brain. HN specifically inhibits neuronal cell death in vitro induced by ß-amyloid (Aß) peptides and by amyloid precursor protein and its gene mutations in familial AD, thereby representing a potential therapeutic lead structure for AD; however, its molecular mechanism of action is not well understood. We report here the identification of the binding epitopes between HN and Aß(1-40) and characterization of the interaction structure through a molecular modeling study. Wild-type HN and HN-sequence mutations were synthesized by SPPS and the HPLC-purified peptides characterized by MALDI-MS. The interaction epitopes between HN and Aß(1-40) were identified by affinity-MS using proteolytic epitope excision and extraction, followed by elution and mass spectrometric characterization of the affinity-bound peptides. The affinity-MS analyses revealed HN(5-15) as the epitope sequence of HN, whereas Aß(17-28) was identified as the Aß interaction epitope. The epitopes and binding sites were ascertained by ELISA of the complex of HN peptides with immobilized Aß(1-40) and by ELISA with Aß(1-40) and Aß-partial sequences as ligands to immobilized HN. The specificity and affinity of the HN-Aß interaction were characterized by direct ESI-MS of the HN-Aß(1-40) complex and by bioaffinity analysis using a surface acoustic wave biosensor, providing a K(D) of the complex of 610 nm. A molecular dynamics simulation of the HN-Aß(1-40) complex was consistent with the binding specificity and shielding effects of the HN and Aß interaction epitopes. These results indicate a specific strong association of HN and Aß(1-40) polypeptide and provide a molecular basis for understanding the neuroprotective function of HN.

Study Information

Provider

pubmed

Year

2012

Date

2012-04-20T00:00:00.000Z

DOI

10.1002/psc.2404

Citations

37

References

43